The Anthelmintic Flubendazole Blocks Human Melanoma Growth and Metastasis and Suppresses Programmed Cell Death Protein-1 and Myeloid-Derived Suppressor Cell Accumulation.
Sign Up to like & getrecommendations! Published in 2019 at "Cancer letters"
DOI: 10.1016/j.canlet.2019.05.026
Abstract: The incidence of melanoma is increasing faster than any other cancer. In recent years, treatment of melanoma and a range of other deadly cancers has involved immunotherapy with programmed cell death protein-1 (PD-1)/PD-1 ligand (PD-L1)… read more here.
Keywords: melanoma; melanoma growth; flubendazole; programmed cell ... See more keywords
Flubendazole inhibits glioma proliferation by G2/M cell cycle arrest and pro-apoptosis
Sign Up to like & getrecommendations! Published in 2017 at "Cell Death Discovery"
DOI: 10.1038/s41420-017-0017-2
Abstract: Flubendazole, FDA-approved anthelmintic, has been widely used in treating testinal parasites. In the recent years, Flubendazole has been reported to exert anticancer activities. On the other hand, little was known about the effects of Flubendazole… read more here.
Keywords: apoptosis; cell cycle; proliferation; flubendazole ... See more keywords
Preclinical toxicity and pharmacokinetics of a new orally bioavailable flubendazole formulation and the impact for clinical trials and risk/benefit to patients
Sign Up to like & getrecommendations! Published in 2019 at "PLoS Neglected Tropical Diseases"
DOI: 10.1371/journal.pntd.0007026
Abstract: Background Flubendazole, originally developed to treat infections with intestinal nematodes, has been shown to be efficacious in animal models of filarial infections. For treatment of filarial nematodes, systemic exposure is needed. For this purpose, an… read more here.
Keywords: orally bioavailable; formulation; flubendazole; toxicity ... See more keywords